SUPERNUS PHARMACEUTICALS, INC. — Operating Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/af4071c7-a363-4af8-a892-86308c1444d8/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-62.3M | 2025-01-01 – 2025-12-31 | evidence 0001356576-26-000011 |
| FY 2024 | $81.7M | 2024-01-01 – 2024-12-31 | evidence 0001356576-25-000017 |
| FY 2023 | $-5.3M | 2023-01-01 – 2023-12-31 | evidence 0001356576-25-000017 |
| FY 2022 | $46.1M | 2022-01-01 – 2022-12-31 | evidence 0001356576-23-000016 |
| FY 2021 | $86.0M | 2021-01-01 – 2021-12-31 | evidence 0001356576-22-000025 |
| FY 2020 | $173.7M | 2020-01-01 – 2020-12-31 | evidence 0001356576-21-000028 |
| FY 2019 | $148.6M | 2019-01-01 – 2019-12-31 | evidence 0001356576-20-000010 |
| FY 2018 | $144.4M | 2018-01-01 – 2018-12-31 | evidence 0001047469-19-000828 |
| FY 2017 | $99.5M | 2017-01-01 – 2017-12-31 | evidence 0001047469-18-001210 |
| FY 2016 | $54.2M | 2016-01-01 – 2016-12-31 | evidence 0001047469-17-001684 |
| FY 2015 | $20.8M | 2015-01-01 – 2015-12-31 | evidence 0001104659-17-003385 |
| FY 2014 | $-5.3M | 2014-01-01 – 2014-12-31 | evidence 0001104659-17-003385 |
| FY 2013 | $-61.9M | 2013-01-01 – 2013-12-31 | evidence 0001047469-14-002791 |
| FY 2012 | $-42.2M | 2012-01-01 – 2012-12-31 | evidence 0001047469-13-002844 |
| FY 2011 | $-37.8M | 2011-01-01 – 2011-12-31 | evidence 0001047469-13-002844 |
| FY 2010 | $-40.1M | 2010-01-01 – 2010-12-31 | evidence 0001047469-13-002844 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
SUPERNUS PHARMACEUTICALS, INC. — all facts · Revenue · Net Income